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A. Tumor Microenvironment 
The tumor microenvironment (TME) is composed of various cell types that includes 
fibroblasts, endothelial cells, tumor cells, and immune cells (Figure 1). The presence of 
inflammatory cells in the tumor stroma has been shown to facilitate tumor development, both in 
experimental models and in the pathogenesis of human cancers. Understanding this TME and 
immune cell recruitment is vital in the pursuit of tumor degradation. It has been shown that 
cancer cells in the TME secrete a variety of cytokines and chemokines that actively recruit 
immune cells into the TME by establishing autocrine and paracrine signaling pathways, which 
directly and indirectly suppress the immune system (Bissell and Hines 2011). Once recruited, the 
immune cells promote tumor growth through two opposing mechanisms. On one hand, TAMs 
secrete cytokines and proteases that facilitate tumor growth and angiogenesis.  In contrast, 
MDSC promote tumor growth by suppressing the function of normal immune cells, which are 




Figure 1: MDSC are constituents of the tumor microenvironment.  
 
B. Myeloid Derived Suppressor Cells 
MDSC represent a heterogeneous population of myeloid cells composed of macrophages, 
granulocytes and dendritic cells that are at early stages of development.  Under physiological 
conditions they represent up to 20-30% of bone marrow cells and ~4% of nucleated cells in the 
spleen (Youn et al. 2008).  However, under pathological conditions such as infections, stress, and 
cancer there is an accumulation of MDSC in lymphoid organs (Trikha and Carson 2014). 
The presence of MDSC was first reported in the blood of patients with head and neck 
cancer, and they were identified as Lin-CD33+CD15+CD34+ cells (Almand et al. 2001).  Human 
MDSC are now broadly classified as CD33+HLADRlow/neg. In mice, MDSC are identified by 
expression of the myeloid markers Gr-1 and CD11b.  Human and murine MDSC are divided into 
two categories: graulocytic and monocytic. Murine models are represented as G-MDSC and M-
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MDSC while human monocytic MDSC express CD14 and granulocytic MDSC express CD15 
(Mandruzzato et al. 2009; Vuk-Pavlović et al. 2010).  
MDSC can suppress the function of normal immune cells, such as NK cells and T cells, 
by creating a suppressive environment in the tumor stroma (Trikha and Carson 2014). Studies 
have shown that T cell function is suppressed by MDSC by a variety of mechanisms such as the 
release of immune-suppressive cytokines, arginase, nitric oxide and reactive oxygen species 
(ROS) (Gabrilovich and Nagaraj 2009; Bissell and Hines 2011). The release of these factors 
leads to decreased immune cell function and helps facilitate tumor progression. 
C. Signaling Pathways 
A number of signaling pathways are implicated during MDSC development and in the 
regulation of their function (Condamine and Gabrilovich 2011). It is widely believed that 
perturbation of signaling pathways involved during myeloid development under pathological 
conditions such as cancer can contribute to the development of MDSC. A number of pathways 
are thought to be linked to MDSC function: Ras, PI3K, IL-6, JAK/STAT, TGF-ß, PGE2 and 





Figure 2: Signaling pathways that affect the proliferation and maturation of cancer cells  
 
Inflammation plays a key role in alerting the body of an intruder during tumor 
progression and general immune defense. IL-6 is a pro-inflammatory cytokine that regulates 
many downstream pathways such as signal transducer and activator of transcription 3 (STAT3). 
This regulation directly leads to cancer cell proliferation, survival, and migration. Additionally, it 
has been shown that up-regulation of IL-6 leads to an increased signaling in the Janus kinase 2 
(JAK) / STAT pathway which has been linked to an increase in accumulation of MDSC in the 
TME (Mundy-Bosse et al. 2011). The JAK/STAT pathway plays a crucial role in mediating 
inflammatory response. Specifically, IL-6 is known to regulate the function and expansion of 
MDSC via  JAK and STAT3 signaling pathway (Mace et al. 2013).  
Another pathway affected by MDSC is the PI3K is the signaling pathway. This pathway  
catalyzes phosphorylation of the 3’OH on phosphatidylinositol in the plasma membrane (Trikha 
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and Carson 2014). PI3K signaling has been found to have effects on cell growth, survival, 
migration, and cellular metabolism. Following the PI3K pathway, the mTOR pathway has been 
shown to work in accordance with the adenosine monophosphate-activated protein kinase 
(AMPK) phosphorylation which is up-regulated during MDSC maturation. Therefore, AMPK 
inhibition can decrease the immunosuppressive potential of MDSC. We hypothesized that 
therapeutic agents like OSU-53 (an AMP kinase inhibitor) can target these signaling pathways, 
and should help in eliminating MDSC from the TME, while making immune-based 






Adenosine monophosphate-activated protein kinase (AMPK) is an enzyme which plays 
an integral role in cellular energy homeostasis and cellular metabolism. When ATP storages 
begins to deplete during physical activity, AMPK is activated leading to energy conversion and 
metabolism through a series of pathways and networks. Moreover, recent studies have linked 
AMPK to cancer cell growth and survival (Inoki et al. 2003). AMPK can also down regulate the 
mammalian target of rapamycin (mTOR) pathway resulting in decreased tumor growth (Lee et 
al. 2011). Recently, an AMPK activator known as metformin has been reported to reduce risk 
and/or mortality in certain types of cancers (Li et al. 2009; Wright and Stanford 2009; Bodmer et 
al. 2010).  
This finding led to the synthesis of OSU-53 (Figure 3), a PPAR γ-inactive derivative 
which directly stimulates AMP  kinase by the Chen Laboratory (Lee et al. 2011). This compound 
targets tumor metabolism by inhibiting tumorigenesis via oncogenic pathway regulation (Lee et 
al. 2011).  
 
   
 




Additionally, AMPK activation has been shown to suppress the expression of the 
inflammatory cytokine IL-6, which plays a key role in promoting breast cancer progression via 
JAK2/STAT3 signaling (Berishaj et al. 2007). This led us to investigate the potential use of 
OSU-53, as therapeutic agent to eliminate or inhibit the suppressive activity of MDSC as a 
potential new therapy for cancer.  This study was designed to investigate whether treatment of 
MDSC with OSU-53, could affect MDSC function by the utilization of a murine MDSC cell line 
known as MSC-2. 
III. Materials and Methods 
A. Cell Lines and Cell Culture 
A murine breast cancer MDSC cell line, MSC-2 (obtained from (Apolloni et al. 2000)) was used 
for in vitro testing. Cells were cultured in RPMI medium (Life Technologies, Paisley, UK) with 
10% FBS, 1% Anti-Anti, and 1% sodium pyruvate.  
B. Annexin V-PI Flow Cytometry 
Annexin- PI staining was used to determine cytotoxicity of the drugs on the MSC-2 cell line.  
The MSC-2 cells were treated with various doses of DMSO (vehicle) or OSU-53 (0-10 μM), and 
placed in an incubator at 37℃ in 5% CO2 Cells were then harvested, re-suspended in annexin 
buffer, and stained with Annexin V and propidium iodine (PI). The cells were run on an LSRII 
flow cytometer (Becton-Dickinson, San José, CA) and then analyzed via FlowjoTM software 
(Treestar, Ashland, OR). 
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C. Western Blot 
MSC-2 cells were cultured with varying amounts of OSU-53 for 18 hours. Cells were lysed via 
RIPA buffer containing protease and phosphatase (Sigma Aldrich, St. Louis, MO). The protein 
lysates were probed for AMPK, p-AMPK, and β–Actin antibodies. 
D. Cell Migration Assay 
The migration of MSC-2 cells treated with varying amounts of OSU-53 were measured in 
response to serum-free supernatant from a breast cancer cell line that has been engineered to 
over-express human HER2 (EMT6-HER2). Briefly, 5 x 104 transfected cells in serum-free 
medium were plated on an 8 μm transwell membrane. The lower compartment of the invasion 
chambers contained a conditioned supernatant from EMT6-HER2 cell cultures utilized as a 
chemoattractant.  After overnight incubation at 37℃ the cells remaining on the upper surface of 
the membrane were remove, while the cells that migrated through the membrane were fixed, 
stained, and counterstained with Dip Quick Stain Kit (Jorgensen Laboratories, Inc., Loveland, 
CO). Photographs were taken of five 20X fields for each filter on an EVOS XL digital inverted 
microscope and cell numbers were enumerated using Image J software from the images (2048 x 




Figure 4: Boyden chamber model for cell migration assay  
 
E. Nitric Oxide (NO) Estimation 
MSC-2 cells treated with varying amounts of drug were cultured for 24 hours.  After this period, 
the supernatant was harvested and quantified for NO using Griess Reagent (Sigma Aldrich, St. 
Louis, MO).  Equal parts Greiss Reagent and sample were mixed together in a 96 well plate and 
absorbance values were recorded at 450 nm using a plate reader. 
F. Enzyme-linked Immuno Assay (ELISA) 
MSC-2 cells treated with varying amounts of drug were cultured for 24 hr.  After this period the 
supernatant analyzed for presence of TNF-α and IL-6.via ELISA using a BIOPLEX kit. 
G. Generation of MDSC 
Normal peripheral blood mononuclear cells (PBMC) were obtained from normal healthy adult 
blood donors (source leukocytes, American Red Cross, Columbus, OH). PBMC were separated 
from source leujocytes by density gradient centrifugation with Ficoll-Paque (GE Healthcare Bio-
Sciences, Pittsburgh, PA) as previously described (Varker et al. 2006). PBMC were cultured in 
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media containing IL-6 and GM-CSF (Peprotech, Rocky Hill, NJ) for a period of six days at 37℃ 
in 5% CO2. During this process, the PBMC were treated with a dose of 5 μM OSU-53 or DMSO 
vehicle control. The media and drug were changed every 2-3 days.   
H. Statistical Analysis  
The data was analyzed using a student’s T test (Microsoft Excel).  
IV. Results 
OSU-53 treatment affects apoptosis of a murine MDSC cell line (MSC-2) 
MSC-2, a mouse MDSC cell line that has been previously shown to mimic MDSC functions, 
was used to examine the effects of the AMPK activator OSU-53 on the function of MDSC in 
vitro. We first wanted to determine a concentration of the OSU-53 that was not cytotoxic to the 
cells. The MSC-2 cells were treated overnight with various doses with DMSO (vehicle) or OSU-
53 (0-10 μM) to determine the dose at which OSU-53 was cytotoxic to MDSC cells. Annexin-PI 
staining showed that OSU-53 did not induce any apoptosis up to a dose of 5 μM (Figure 5A-5B). 
However, there was a significant increase in the number of apoptotic cells at a dose of 10 μM. 





            
Figure 5: A&B.  The effects of OSU-53 on apoptosis of a murine MDSC cell line. MSC-2 cells 
were treated with OSU-53 for 18 hours. Cells were then washed and stained with Annexin V-PI. 
(A) FACS profile of MSC-2 treated with OSU-53.  (B) Percentage of apoptotic cells was 
measured by flow cytometry 
 
OSU-53 treatment leads to the activation of AMPK in MDSC 
OSU-53 is a PPAR-inactive derivative that has been shown to stimulate AMPK kinase in triple 
negative breast cancer cells (TNBC) (Lee et al. 2011) (Figure 6). We therefore wanted to 
investigate whether OSU-53 could also activate AMPK activity in MSC-2 cells.  Western blot 
analysis showed that OSU-53 treatment did not affect the levels of AMPK in MSC-2 cells 
(Figure 6). However, there was an induction in the levels of phosphorylation of AMPK following 





Figure 6: Effect of OSU-53 on phosphorylated AMPK. Western blot of MSC-2 cells treated 
with OSU-53 probed for p-AMPK, AMPK, and ß-Actin (loading control). 
 
OSU-53 treatment leads to an attenuation of NO levels    
Nitric oxide is one the key molecules produced by MDSC that is involved in immune 
suppression of NK and T cells functions (Bogdan, 2001).  To examine the affect OSU-53 on the 
levels of NO, MSC-2 cells were treated with the indicated doses of OSU-53 and stimulated with 
LPS for 24 hours.  Following the incubation, the supernatant were collected and analyzed for 
levels of nitrite using Griess reagent. Activation of MDSC with LPS resulted in an increase in 
the levels of nitrite to 25 μM. There was a 3-fold decrease in the levels of NO in the MSC-2 cells 




Figure 7: OSU-53 decreases nitric oxide production. MSC-2 cells were treated with indicated 
doses of OSU-53 for 12 hrs and then stimulated with LPS. The levels of nitrite were measured in 
the supernatant using Griess Reagent. 
 
OSU-53 treatment reduces MDSC migration  
Tumor cells secrete cytokines and chemokines that help in the recruitment of MDSC into the 
tumor microenvironment (Gabrilovich and Nagaraj 2009). We performed migration assay to 
determine whether treatment of MDSC with OSU-53 affected their ability to migrate in response 
to factors produced by tumor cells. These assays showed a significant reduction (p<0.001) in the 
number of MSC-2 cells treated with 5 μM of OSU -53 when compared to DMSO treated control 
(Figure 8).  
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Figure 8: Effect of OSU-53 on cell migration. (A) Digital image of migrated MSC-2 cells. (B) 
OSU-53 treatment leads to reduced MDSC migration. 
 
Reduced levels of IL-6 and TNF-α in OSU-53 treated cells  
Since it has been shown that various signaling pathways are involved in the regulation of MDSC 
expansion and function (Trikha and Carson 2014), we next wanted to examine the whether OSU-
53 treatment affected the secretion of pro-inflammatory cytokine like IL-6 and TNF-Αby MSC-2 
cells. Data from the array of MSC-2 cells treated with varying doses of OSU-53 showed that 





INF-γ (data not shown). Interestingly, there was a significant increase in the levels of IL-6 and 
TNF-a by MSC-2 following stimulation with LPS.  Moreover, treatment of MSC-2 cells with 
OSU-53 (5 μM) results in a reduction in the levels of IL-6 (2.9 fold) and TNF-α (1.5 fold) 
(Figure 9).  Both these cytokine have been shown to have an important role in the regulation of 
MDSC function. Our results are consistent with the previous studies that have shown that OSU-
53 can affect the levels of IL-6 in tumor cells. This is, however, the first report to our knowledge 





Figure 9:  OSU-53 affects the level of cytokines measured by ELISA. (A) Relatively no effect 
on TNF-α. (B) OSU-53 decreases production of IL-6 cytokine. 
 
MDSC generation is not affected by OSU 53 
Cytokines like IL-6 and TNF-α are involved in the generation and expansion of MDSC during 
tumorigenesis (Condamine and Gabrilovich 2011). We therefore wanted to investigate whether 
treatment with OSU-53 could affect the generation of MDSC. PBMC treated with a DMSO 
control resulted in the generation of MDSC. The addition of OSU 53 did not impact the ability of 





• FACS analysis of cells treated with OSU-53 showed that 0.5-5 µM did not induce cell 
apoptosis. 
• There was an increase in levels of activated p-AMPK after the treatment of MSC-2 cells 
with OSU-53. 
• Treatment of MSC-2 with OSU-53 significantly (p<0.05) decreased NO production in 
MSC-2 cells by 1.5 fold. 
• Cytokine levels of both IL-6 and TNF-α decreased in response to OSU-53 treatment.  
• Cell migration was significantly (p<0.05) decreased in response to tumor supernatant 
after treatment of MSC-2 cells with OSU-53. 
VI. Summary 
Our results showed that OSU-53 was not cytotoxic at concentrations ranging from 0.5 μM -5 μM 
as determined by Annexin V staining. Interestingly, treatment of MSC-2 with OSU-53 (5 μM) 
led to a significant (p<0.05) reduction in the ability of these cells to migrate in response to tumor 
cells in vitro. There was also a decrease in production by MSC-2 cells following treatment with 
the drug. Furthermore, there was two-fold reduction in the levels of pro-inflammatory cytokine 
IL-6 which is linked to the activation of MDSC.  In summary, OSU-53 can modulate MDSC 
function in vitro (Figure 10) by inhibiting the function of the murine MDSC cell line, MSC-2.    
Future studies will be aimed at investigating whether OSU-53 can modulate MDSC function in 
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